Details

Autor(en) / Beteiligte

• Torriani, Francesca J
• Rodriguez-Torres, Maribel
• Rockstroh, Jürgen K
• Lissen, Eduardo
• Gonzalez-García, Juan
• Lazzarin, Adriano
• Carosi, Giampiero
• Sasadeusz, Joseph
• Katlama, Christine
• Montaner, Julio
• Sette, Hoel
• Passe, Sharon
• De Pamphilis, Jean
• Duff, Frank
• Schrenk, Uschi Marion
• Dieterich, Douglas T

Titel

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected Patients

Ist Teil von

• The New England journal of medicine, 2004-07, Vol.351 (5), p.438-450

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• In this randomized trial involving patients with chronic hepatitis C who were also infected with the human immunodeficiency virus (HIV), peginterferon alfa-2a plus ribavirin was more effective than interferon alfa-2a plus ribavirin or peginterferon alfa-2a plus placebo (rates of sustained virologic response, 40 percent, 12 percent, and 20 percent, respectively). The rates of response were not as high as in previous studies involving HIV-negative patients. Potent antiretroviral therapy has reduced the morbidity and mortality associated with untreated human immunodeficiency virus (HIV) infection. 1 , 2 At the same time, the pattern of morbidity and mortality among HIV-infected persons has shifted, and clinicians responsible for the care of HIV-infected persons have been confronted with new challenges. Complications associated with concurrent hepatitis C virus (HCV) infection have emerged as one of the most frequent and complex issues in the care of patients with HIV infection and the acquired immunodeficiency syndrome (AIDS). 3 , 4 The current standard of care for chronic infection with HCV in persons without other infections is pegylated . . .